A detailed history of Stonegate Investment Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Stonegate Investment Group, LLC holds 6,468 shares of VRTX stock, worth $3 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
6,468
Previous 6,742 4.06%
Holding current value
$3 Million
Previous $3.16 Million 4.81%
% of portfolio
0.08%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$460.0 - $505.78 $126,040 - $138,583
-274 Reduced 4.06%
6,468 $3.01 Million
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $1.41 Million - $1.75 Million
3,598 Added 114.44%
6,742 $3.16 Million
Q1 2024

Apr 22, 2024

SELL
$407.69 - $446.08 $53,815 - $58,882
-132 Reduced 4.03%
3,144 $1.31 Million
Q4 2023

Jan 23, 2024

SELL
$343.0 - $410.68 $52,822 - $63,244
-154 Reduced 4.49%
3,276 $1.33 Million
Q3 2023

Oct 24, 2023

SELL
$338.18 - $362.46 $132,566 - $142,084
-392 Reduced 10.26%
3,430 $1.19 Million
Q2 2023

Jul 26, 2023

SELL
$314.42 - $351.91 $943 - $1,055
-3 Reduced 0.08%
3,822 $1.35 Million
Q1 2023

Apr 20, 2023

SELL
$283.23 - $323.1 $133,118 - $151,857
-470 Reduced 10.94%
3,825 $1.21 Million
Q4 2022

Jan 24, 2023

SELL
$285.76 - $321.48 $12,573 - $14,145
-44 Reduced 1.01%
4,295 $0
Q3 2022

Oct 28, 2022

SELL
$273.83 - $305.53 $101,317 - $113,046
-370 Reduced 7.86%
4,339 $1.26 Million
Q2 2022

Aug 09, 2022

SELL
$234.96 - $292.55 $116,070 - $144,519
-494 Reduced 9.49%
4,709 $1.33 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $120,452 - $141,967
-544 Reduced 9.47%
5,203 $1.36 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $1.02 Million - $1.28 Million
5,747 New
5,747 $1.26 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Stonegate Investment Group, LLC Portfolio

Follow Stonegate Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonegate Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonegate Investment Group, LLC with notifications on news.